MDS Proteomics is Ready for Big Pharma, Executive Says | GenomeWeb

NEW YORK, June 21 - After building its proteomics platform with the help of IBM, Agilent, and other technology providers, MDS Proteomics is ready to start partnering with pharmaceutical companies who will pay MDS Proteomics for its services, chief business officer Caroline Popper told GenomeWeb.

"Our partnering strategy was to make the platform robust," she said. "And now we're ready to put in the product relationships, and we're heavily in negotiations with major pharmaceutical companies."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.